Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
Conditions
Interventions
Pembrolizumab Formulated with Berahyaluronidase Alfa
Pemetrexed
+7 more
Locations
110
United States
St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023)
Phoenix, Arizona, United States
Clermont Oncology Center ( Site 0018)
Clermont, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 0010)
Orange City, Florida, United States
University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0022)
Chicago, Illinois, United States
Orchard Healthcare Research Inc. ( Site 0011)
Skokie, Illinois, United States
Franciscan Health Lafayette East ( Site 0020)
Lafayette, Indiana, United States
Start Date
February 14, 2023
Primary Completion Date
July 12, 2024
Completion Date
May 22, 2028
Last Updated
September 11, 2025
NCT06996782
NCT06975293
NCT06343402
NCT06955988
NCT06512051
NCT06216301
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions